Ology Bioservices, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Ology Bioservices, Inc.
With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.
Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.
The biomanufacturing firm National Resilience has raised more than $2bn in venture capital and millions more in fees from government and industry contracts since 2020. Also, Code Biotherapeutics raised $75m in series A cash, Concert grossed $66.4m and Amarin is cutting US jobs.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Contract Research, Toxicology Testing-CRO
- Consulting Services
- Controlled Release
- Topical Delivery
- Large Molecule
- Nanotechnology, Chips, etc.
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Other Names / Subsidiaries
- Vion Pharmaceuticals
- Nanotherapeutics, Inc
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.